Related Posts
- RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment
Background With the successful development of modern immunotherapy, immune checkpoint inhibitors (ICIs) are currently considered…
- 272 PD-L1 CAR engineered K-NK cells to target PD-L1+ or PD-L1- tumors
Background Chimeric antigen receptor (CAR) engineered immune cells have shown unprecedented efficacy in Relapsed/Refractory hematological…